Genkyotex
Updated: March 19, 2026
Elias Papatheodorou, CEO
Country: Switzerland | Funding: $87.1M (+)
Founded: 2006
Website: http://www.genkyotex.com/
Genkyotex is the leading developer of NOX inhibitors. We are developing first-in-class, small molecule therapeutics that selectively inhibit NOX enzymes. NOX enzymes are key drivers in multiple diseases including fibrotic, inflammatory, cardiovascular and CNS diseases and oncology.
Founded: 2006
Website: http://www.genkyotex.com/
Genkyotex is the leading developer of NOX inhibitors. We are developing first-in-class, small molecule therapeutics that selectively inhibit NOX enzymes. NOX enzymes are key drivers in multiple diseases including fibrotic, inflammatory, cardiovascular and CNS diseases and oncology.
